The tender offer will expire at midnight, New York City time, on Thursday, March 11, 2010, unless extended in accordance with the terms of the tender offer and the applicable rules and regulations of the SEC. The closing of the tender offer is subject to the satisfaction or waiver of certain conditions, including, among others, the tender of a majority of Home Diagnostics’ shares in response to the offer, there not having been a material adverse change with respect to Home Diagnostics, and other customary closing conditions. The tender offer is not subject to a financing condition. The Purchaser may, in its sole discretion, provide for a subsequent offering period for a further period of time not to exceed 20 business days in accordance with Rule 14d-11 under the Securities Exchange Act of 1934 following its acceptance in the tender offer of a majority of Home Diagnostics’ shares.
About Nipro Corporation
Nipro Corporation (Tokyo Stock Exchange and Osaka Stock Exchange Ticker Code 8086), founded in 1954, is engaged directly and through its subsidiaries principally in the development, manufacture and sale of medical devices, pharmaceutical products and medical and glass products. Nipro’s medical device division is engaged in the manufacture and sale of medical devices and its related products, the development, manufacture and sale of cell culturing-related products, as well as the development and sale of diabetes-related products. Nipro also currently markets its own insulin pump through its U.S. diabetes division. Nipro’s pharmaceutical division is engaged in the research, manufacture and sale of pharmaceuticals, such as blood derivatives. The instrument division of Nipro manufactures and sells glass pipes and other glass products, including the inner bottles of thermos bottles. Nipro and its subsidiaries also sell medical device manufacturing equipment and conduct real estate leasing and non-life insurance agency businesses. For more information please visit
About Home Diagnostics
Based in Fort Lauderdale, Florida, Home Diagnostics (NASDAQ: HDIX) is a leading developer, manufacturer and marketer of diabetes management products. Home Diagnostics offers a portfolio of high-quality blood glucose monitoring systems that spans the spectrum of features and benefits to help every person with diabetes better monitor and manage their disease. The Home Diagnostics product line includes TRUE2go™, TRUEresult®, TRUEtrack®, TRUEbalance™, Sidekick®, TRUEread® and Prestige IQ® blood glucose monitoring systems. The products are available in more than 45,000 pharmacies throughout the U.S. Home Diagnostics is the exclusive co-brand supplier of blood glucose monitoring systems for leading pharmacies including CVS, Rite Aid and Walgreens, as well as distributors such as AmerisourceBergen, Cardinal Health, McKesson, Invacare and Liberty Medical. Home Diagnostics was named one of Forbes magazine’s “200 Best Small Companies” in 2008, and in 2009 received several recognitions for the company’s TRUE2go blood glucose meter, including a Medical Design Excellence Award (MDEA) and a Gold
Award in the Medical/Test Equipment category as part of
Annual Excellence in Design (EID) Awards Competition. For more information please visit
This announcement and the description contained herein is neither an offer to purchase nor a solicitation of an offer to sell shares of Home Diagnostics. Nipro and the Purchaser have filed with the SEC a Tender Offer Statement on Schedule TO containing an offer to purchase, form of letter of transmittal and other documents relating to the tender offer, and Home Diagnostics has filed with the SEC a Solicitation/Recommendation Statement on Schedule 14D−9 with respect to the tender offer. Nipro, the Purchaser and Home Diagnostics intend to mail these documents to the stockholders of Home Diagnostics. These documents contain important information about the tender offer and stockholders of Home Diagnostics should read them carefully before any decision is made with respect to the tender offer. Stockholders of Home Diagnostics will be able to obtain a free copy of these documents and other documents filed by Home Diagnostics with the SEC at the website maintained by the SEC at
. In addition, stockholders of Home Diagnostics may obtain a free copy of these documents from Home Diagnostics by contacting Home Diagnostics, Inc. at 2400 N.W. 55
Court, Ft. Lauderdale, FL 33309, attention Peter Ferola, General Counsel.
None of the information included on any internet website maintained by Nipro Corporation, Home Diagnostics or any of their affiliates, or any other internet website linked to any such website, is incorporated by reference or otherwise made a part of in this press release